MLTX MoonLake Immunotherapeutics AG
Price Chart
Executive Summary
MoonLake announced a successful final pre-BLA meeting with the FDA, aligning on submission plans and label strategy for sonelokimab in hidradenitis suppurativa (HS), including inclusion of adolescent data. The BLA submission is planned for end of September 2026, with potential Priority Review decision by end of November 2026. Q1 2026 cash position of $357.9M provides runway to end of 2027, with up to $400M in non-dilutive debt available.
Actionable Insight
The successful pre-BLA meeting significantly de-risks the regulatory path for sonelokimab in HS, a key catalyst. Monitor for BLA acceptance and Priority Review decision by end of November 2026, and upcoming data readouts (52-week VELA data in Q2 2026, IZAR-1 PsA data mid-2026). Cash runway through end of 2027 and $400M debt facility provide ample funding. The stock may re-rate on reduced regulatory risk.
Key Facts
- Positive final pre-BLA meeting with FDA; no remaining gaps identified for HS program
- BLA submission for sonelokimab in HS planned for end of September 2026
- FDA acceptance and Priority Review decision expected by end of November 2026
- Proposed label expected to include MIRA trial's ~43% HiSCR75 response and ~29 ppt delta-to-placebo
- First commercial launch in US expected in second half of 2027
- Q1 2026 cash, cash equivalents and short-term marketable debt securities: $357.9M
- Cash runway expected to end of 2027; up to $400M non-dilutive debt facility with Hercules Capital available
- R&D expenses $54.5M for Q1 2026, similar to $56.0M in Q4 2025
- Net loss $69.7M for Q1 2026 vs $63.0M in Q4 2025
Financial Impact
No revenue or EPS reported (pre-revenue biotech). Cash burn rate ~$70M/quarter. BLA submission de-risks path to approval and potential $15B HS market by 2035.
Risk Factors
- BLA submission or review could face delays or unexpected FDA requests
- Priority Review may not be granted, extending review timeline
- Commercial launch in 2H 2027 is subject to FDA approval and could be delayed
- Competition from approved IL-17 inhibitors (e.g., secukinumab, bimekizumab) in HS
- Clinical data from ongoing trials (VELA-TEEN, IZAR) could disappoint
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291475 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
2d ago
|
Institutional Cluster
| $17.99 awaiting T+5 | awaiting T+5 | — | $18.69 (−3.89%) |
|
Jun 1, 2026
12d ago
|
8-K
| $18.82 $17.90 | ▼ −4.89% | ▼ −2.14% | $18.69 (−0.69%) |
|
May 10, 2026
4w ago
|
Press Release
| $18.84 $16.44 | ▼ −12.74% | ▼ −12.65% | $18.69 (−0.80%) |
|
Apr 1, 2026
10w ago
|
144
| $16.52 $19.41 | ▼ −17.49% | ▼ −13.73% | $18.69 (−13.14%) |
|
Mar 28, 2026
10w ago
|
Press Release
| $16.93 $17.08 | ▲ +0.89% | ▼ −3.41% | $18.69 (+10.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access